| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Brege Laura | Director | C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY | /s/ Judit Ryvkin, Attorney-in-Fact | 12 Sep 2025 | 0001365619 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Common Stock | Options Exercise | $255,000 | +17,000 | +108% | $15.00 | 32,703 | 11 Sep 2025 | Direct | |
| transaction | MIRM | Common Stock | Sale | $1,152,939 | -15,509 | -47% | $74.34 | 17,194 | 11 Sep 2025 | Direct | F1 |
| transaction | MIRM | Common Stock | Sale | $111,929 | -1,491 | -8.7% | $75.07 | 15,703 | 11 Sep 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MIRM | Stock Option (right to buy) | Options Exercise | $0 | -17,000 | -100% | $0.000000 | 0 | 11 Sep 2025 | Common Stock | 17,000 | $15.00 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The weighted average sale price for the transaction reported was $74.34, and the range of prices were between $73.73 and $74.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F2 | The weighted average sale price for the transaction reported was $75.07, and the range of prices were between $74.745 and $75.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| F3 | The stock option is fully vested. |